Abstract:Inactivation of p53 is present in almost every tumor, and hence, p53-reactivation strategies are an important aspect of cancer therapy. Common mechanisms for p53 loss in cancer include expression of p53-negative regulators such as MDM2, which mediate the degradation of wildtype p53 (p53α), and inactivating mutations in the TP53 gene. Currently, approaches to overcome p53 deficiency in these cancers are limited. Here, using non-small cell lung cancer and glioblastoma multiforme cell line models, we show that two alternatively spliced, functional truncated isoforms of p53 (p53β and p53γ, comprising exons 1 to 9β or 9γ, respectively) and that lack the C-terminal MDM2-binding domain have markedly reduced susceptibility to MDM2-mediated degradation but are highly susceptible to nonsense-mediated decay (NMD), a regulator of aberrant mRNA stability. In cancer cells harboring MDM2 overexpression or TP53 mutations downstream of exon 9, NMD inhibition markedly upregulates p53β and p53γ and restores activation of the p53 pathway. Consistent with p53 pathway activation, NMD inhibition induces tumor suppressive activities such as apoptosis, reduced cell viability, and enhanced tumor radiosensitivity, in a relatively p53-dependent manner. In addition, NMD inhibition also inhibits tumor growth in a MDM2-overexpressing xenograft tumor model. These results identify NMD inhibition as a novel therapeutic strategy for restoration of p53 function in p53-deficient tumors bearing MDM2 overexpression or p53 mutations downstream of exon 9, subgroups that comprise approximately 6% of all cancers.

MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation

Negative Regulation of p53 Functions by Daxx and the Involvement of MDM2

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

Autoactivation of the MDM2 E3 Ligase by Intramolecular Interaction

Secondary Interaction Between MDMX and P53 Core Domain Inhibits P53 DNA Binding.

Mdm2 Inhibits Axin-Induced P53 Activation Independently Of Its E3 Ligase Activity

P300/mdm2 Complexes Participate in MDM2-mediated P53 Degradation.

Mdm2 is A Negative Regulator of P21(Waf1/Cip1), Independent of P53

Interplay Between MDM2, MDMX, Pirh2 and COP1: the Negative Regulators of P53

Complex Structures of Human MDM2 with Interacting Proteins Reveal the Regulation Mechanism of P53

MDM2 Promotes Genome Instability by Ubiquitinating the Transcription Factor HBP1

Bivalent binding of p14ARF to MDM2 RING and acidic domains inhibits E3 ligase function

Acidic Domain is Indispensable for MDM2 to Negatively Regulate the Acetylation of P53

Interactions Between P53 And Mdm2 In A Mammalian-Cell Cycle Checkpoint Pathway

Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase.

Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer.

Mutant p53 sequestration of MDM2 acidic domain inhibits E3 ligase activity.

Structure of Human Mdm2 Complexed with Rpl11 Reveals the Molecular Basis of P53 Activation

Acetylation Of P53 Inhibits Its Ubiquitination By Mdm2

Phosphorylation by Casein Kinase I Promotes the Turnover of the Mdm2 Oncoprotein via the SCFβ-TRCP Ubiquitin Ligase

Stabilization of E2F1 Protein by MDM2 Through the E2F1 Ubiquitination Pathway